Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a positive outlook with a 175% revenue increase and improved net loss figures. The company's strategic plans, including international expansion and partnerships, are promising. However, uncertainties in regulatory timelines and lack of specific shareholder return plans temper enthusiasm. The Q&A suggests optimism about future growth and expense reductions, despite some unclear management responses. Overall, the positive revenue growth and strategic initiatives outweigh the concerns, suggesting a positive stock price movement in the near term.
Revenue $1,100,000, an increase of $700,000 (175%) compared to $400,000 a year ago. This growth was driven by six new hospital signings and two contract renewals.
Gross Profit Loss $200,000 loss, improved from a $400,000 loss year-over-year. The improvement was due to a reduction in losses despite costs exceeding revenue due to one-time upgrade costs and non-cash headwinds.
Research and Development Expenses $3,000,000, a decrease of $3,800,000 (56%) from $6,800,000 in the same quarter last year. The decrease was primarily attributed to lower salaries and stock-based compensation.
SG&A Expenses $7,700,000, down $2,100,000 (21%) from $9,800,000 year-over-year. This decrease was mainly due to reduced salaries and stock-based compensation costs.
Other Expense $2,400,000, an increase of $2,100,000 compared to $300,000 in the previous year. The increase was mostly non-cash and attributed to the extinguishment of the Avenue loan.
Net Loss $13,000,000, or a loss of $0.15 per share, improved from a net loss of $16,200,000 or a loss of $0.5 per share in the same quarter last year.
Net Cash Burn $7,600,000, which was more than 30% lower than the prior quarter ended 09/30/2024. This decrease was mainly due to cost reductions implemented earlier in the fiscal year.
Cash, Cash Equivalents and Marketable Securities $10,900,000 as of 12/31/2024, which is expected to support current operating plans through spring 2026, contingent on meeting internal revenue estimates and controlling costs.
LungFit PH System: Six new hospital starts and two contract renewals, indicating strong market engagement and customer satisfaction.
Next Generation LungFit PH: Demonstrated at ARC Annual Meeting with strong feedback; expected PMA submission to FDA shortly.
LungFit PH CE Mark Approval: Received CE Mark approval allowing marketing in the EU and other countries, triggering a $1,000,000 milestone payment.
Market Expansion in Europe and Asia Pacific: Partnerships with HealthcareLinks and business Asia Consultants to enhance distribution and sales in international markets.
U.S. Market Positioning: Expecting significant market share growth in the U.S. due to improved product performance and commercial infrastructure.
Operational Efficiencies: Cost reductions implemented, including a 30% reduction in staff and closing two offices, leading to lower cash burn.
Customer Engagement Process: Strengthened customer engagement process resulting in positive feedback and improved customer service.
Strategic Shift in Culture: Cultural shift within the company under new Chief Commercial Officer, leading to improved morale and customer service.
Focus on Regulatory Approvals: Ongoing discussions with FDA for PMA supplement for cardiac surgery, indicating a strategic focus on regulatory pathways.
Regulatory Risks: The ongoing discussions with the FDA regarding the PMA supplement for the LungFit PH label expansion to include cardiac surgery are uncertain, with potential delays due to staffing changes at the FDA.
Competitive Pressures: The company faces competition in the nitric oxide market, particularly as no nitric oxide products are currently approved for cardiac surgery in the U.S., which could impact market share.
Supply Chain Challenges: The company has incurred one-time costs of $300,000 to upgrade existing devices, indicating potential supply chain issues that could affect operational costs.
Economic Factors: The company anticipates cash burn to continue but at a lower rate, contingent on meeting internal revenue estimates and controlling costs, highlighting economic pressures on financial performance.
Market Entry Risks: The company is expanding internationally, but the timing and success of market entry in various regions depend on regulatory processes, which can be unpredictable.
Customer Engagement: While there is positive feedback from existing customers, the company must maintain strong customer engagement to ensure continued growth and avoid losing contracts.
New Hospital Signings: During the quarter, Beyond Air saw six new hospital starts and two hospitals renew their contracts, one for three years.
Customer Engagement: The company has strengthened each stage of the customer engagement process, leading to overwhelmingly positive feedback on the LungFit PH device.
Partnerships: Beyond Air has established partnerships with HealthcareLinks and Trilimet to enhance distribution and engagement with military and veterans administration hospitals.
CE Mark Approval: LungFit PH received CE Mark approval, allowing marketing in the EU and triggering a $1,000,000 milestone payment from Getz Healthcare.
Next Generation LungFit PH: The next generation LungFit PH system is expected to be ready for FDA submission shortly, with strong interest from hospitals.
Global Market Expansion: The company is working with business Asia Consultants to expand LungFit PH sales in Europe, South America, Asia Pacific, and the Middle East.
Revenue Growth: Beyond Air expects sequential quarterly revenue growth to continue throughout the year.
Revenue Guidance for FY26: Revenue guidance for fiscal year 2026 will be provided during the fiscal year 2025 year-end conference call in June.
Cash Burn: Net cash burn in the quarter was $7,600,000, expected to trend lower in the March quarter.
Market Share Expectations: The updated LungFit PH is poised to take significant market share in the U.S. and globally.
Phase 1b Trial Data: Top line data from the Phase 1b study for low volume ultra high concentration nitric oxide in cancer patients is anticipated around the end of calendar 2025.
Shareholder Return Plan: The company has not announced any specific share buyback or dividend program during this call. However, they mentioned a focus on improving profitability and managing cash burn, which may indirectly support shareholder returns in the future.
The earnings call summary indicates strong financial performance with a 128% YoY revenue increase, reduced gross losses, and significant cost reductions. The Q&A section reveals positive sentiment towards the second-gen LungFit PH, expected to drive further growth, despite supply chain challenges. The company's strategic international expansion and new business model also contribute positively. However, the vague management responses and updated guidance suggest some uncertainty, tempering the overall sentiment. Considering these factors, the stock price is likely to experience a positive movement, especially given the significant revenue growth and cost control.
The earnings call presents strong revenue growth, optimistic guidance, international expansion, and reduced expenses. The Q&A section reveals confidence in achieving guidance, despite some uncertainties in hospital contracts and PMA filings. Cash reserves are solid, supporting operations well into 2026. The company's strategic moves, including the Premier agreement and international partnerships, are expected to drive growth. While management's lack of specific details could be a concern, the overall sentiment is positive, with potential for stock price appreciation in the coming weeks.
Despite a strong revenue increase and reduced losses, concerns like logistical challenges, unclear FDA approval timelines, and lack of immediate impact from new product versions temper enthusiasm. The financial performance shows improvement, but the absence of a share repurchase program and management's vague responses during the Q&A add uncertainty. Thus, a neutral stock price movement is expected over the next two weeks.
The earnings call presents a positive outlook with a 175% revenue increase and improved net loss figures. The company's strategic plans, including international expansion and partnerships, are promising. However, uncertainties in regulatory timelines and lack of specific shareholder return plans temper enthusiasm. The Q&A suggests optimism about future growth and expense reductions, despite some unclear management responses. Overall, the positive revenue growth and strategic initiatives outweigh the concerns, suggesting a positive stock price movement in the near term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
